
Amara Fitter started having seizures at seven months old, sometimes as many as 100 in a single day. Two months later, her mother Nasha Fitter got the diagnosis that would upend her family's life: FOXG1 syndrome, a rare genetic condition doctors said would leave Amara unable to walk or talk, severely intellectually delayed and prone to seizures for the rest of her life.
“At 9 months, I get this devastating diagnosis,” Fitter said, according to KTNV, which reported she was told nothing could be done for her daughter. Rather than accept that answer, Fitter became involved in rare-disease research and advocacy, work that eventually led her to Las Vegas this week to talk about a new AI tool built for families living through the same nightmare she once faced.
That tool is called Ari, developed by Citizen Health, the company Fitter co-founded with Farid Vij in 2023, according to CNBC. Ari is designed to help rare-disease patients and families organize medical records, prepare for doctor appointments and work through insurance denials, per KTNV's report. Fitter said the tool is free for rare-disease families and was built to be simple and conversational, and families can sign up for it through Citizen Health by providing information about their specific condition.
A Mother's Research Became a Treatment
Fitter didn't stop at building software. KTNV reports that a nonprofit research organization she helped build developed a genetic therapy for Amara's condition in less than a decade, a pace advocates say reflects a broader shift in how rare-disease treatments get made. Fitter has described that shift herself, telling PharmaBoardroom that “we are seeing a new generation of sophisticated parents and patients enter this space. These are people who receive a diagnosis and refuse to wait for industry to take its time finding a cure,” according to the publication's interview with her.
That foundation's work has since moved into clinical testing. According to University at Buffalo, the FDA approved an Investigational New Drug application for FRF-001, a gene therapy developed for FOXG1 syndrome, clearing the way for trials to begin. Per the same account, the planned first-in-human trial will run across multiple sites and is independently sponsored by the FOXG1 Research Foundation, which says on its own site that it has become the first rare-disease foundation to independently drive a gene-therapy program through global, multi-site clinical trials. The foundation told the University at Buffalo it has raised $14.5 million so far through its “Yes, They Can” campaign to push FRF-001 toward regulatory approval. ClinicalTrials.gov describes the trial's goal as determining whether FRF-001 is safe, tolerable and effective for children and adults with FOXG1 syndrome.
The Weight Rare-Disease Families Carry
The burden on families like the Fitters is part of what drove the push for tools like Ari. CNBC reported that Vij has said parents of rare-disease patients spend an average of 53 hours a week on care beyond ordinary parenting duties — a second full-time job layered atop diagnosis, treatment and advocacy. Citizen Health says it now has more than 8,000 rare-disease patients on its platform across more than 350 diseases, according to CNBC's reporting.
National estimates suggest the scale of the challenge extends far beyond any one family. An NIH page estimates that 25 million to 30 million Americans are affected by rare diseases collectively, while a medical-journal snippet published on PMC puts the figure at nearly 30 million and notes that patients wait an average of six years for a definitive diagnosis, often seeing as many as 12 specialists along the way.
Bringing the Mission to HLTH
Fitter is bringing that mission to HLTH 2026, a healthcare innovation conference in Las Vegas that KTNV describes as expected to draw more than 12,000 people, with speakers including Dr. Oz, U.S. Sen. Mark Kelly and Michael Phelps. Event-date details vary across the available sourcing: KTNV reported the conference was scheduled to begin Tuesday, Nov. 17, in Las Vegas, while HLTH's own event page lists HLTH USA 2026 as running Nov. 15 through 18 at the Venetian Expo Center, as noted by HLTH.
Citizen Health, for its part, is clear that Ari has limits. The company says on its site that Ari is not intended to give medical advice, diagnose or prescribe conditions, or replace a user's existing care team — it's a support tool, not a substitute for doctors.
For Fitter, the stakes remain deeply personal. She said she hopes Amara will one day be able to speak a few words, including “help,” and she has spoken about her worry that Amara might be unable to tell anyone if someone hurt her after her parents are gone. Fitter told KTNV she wants rare-disease families included in discussions about the future of medicine, and said Nevada families facing similar diagnoses are not alone and can find helpful tools in tools like Ari.









